Maryland is currently home to 2671 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
NCT06744283
Recruiting
Background: Fanconi anemia (FA) is a rare, inherited cancer syndrome. FA causes a range of physical issues. Children with FA may have abnormal features; these may include a small head and eyes and issues with their internal organs. Young adults have a much higher risk of cancer. To screen for these cancers, people with FA may need to pursue many visits with different doctors. This constant need for cancer screening may cause anxiety for people with FA. Objective: To learn more about anxiety r... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/13/2025
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Fanconi Anemia
Register for Updates
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
NCT06742996
Recruiting
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Mantle Cell Lymphoma, B Cell Lymphoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
08/13/2025
Locations: Pharmasite Research, Inc. ( Site 0167), Baltimore, Maryland
Conditions: Alzheimer Disease, Dementia
Register for Updates
Predicting Future Errors During Skill Performance
NCT06707207
Recruiting
Background: Many tasks people do every day require a series of individual movements. Control over these movements is called motor skills. But even highly skilled people can make mistakes. Researchers have found that they can predict when a person will make a mistake 0.1 second before it happens. Now, they want to find out if they can increase that time up to 1 second-long enough to warn the person and prevent the mistake. Objective: To see if motor skill errors can be detected up to 1 second... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy
Register for Updates
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140
Recruiting
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/13/2025
Locations: Centennial Medical Group, Columbia, Maryland
Conditions: COVID-19 SARS-CoV-2 Infection
Register for Updates
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
NCT06676059
Recruiting
Background: About 1.5 million adults in the US enter alcohol or substance use treatment programs each year. Unfortunately, more than half of patients do not finish their program. For those who start treatment, about 70% return to substance use within weeks or months after starting treatment. To discover why patients drop out of treatment and return to substance use - and what can be done about it - researchers need to learn more about people who use drugs and alcohol. Objective: To create a d... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/13/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Alcoholism, Substance-Related Disorders
Register for Updates
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
NCT06664814
Recruiting
Background: Focal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein loss in the urine, which can worsen kidney function. The kidneys may fail over time, and dialysis or a kidney transplant may be needed. Other treatments for this disease do not always work and often have adverse effects. Better treatments for FSGS are needed. Objective: To test a study drug (ManNAc) in people with FSGS. Eligibility: Peop... Read More
Gender:
ALL
Ages:
Between 18 years and 115 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic Syndromes
NCT06630650
Recruiting
Background: Congenital myasthenic syndromes (CMSs) are a group of inherited disorders that affect how the nerves communicate with muscles. These can cause many problems that affect how people can move and use their bodies. Objective: This is a natural history study to learn more about how CMSs affect the body and cause changes over time. Eligibility: People aged 6 months or older with a CMS. The study will focus on DOK7- and COLQ-related CMSs, as well as other forms. Design: Participants... Read More
Gender:
ALL
Ages:
Between 6 months and 99 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myasthenic Syndromes, Congenital
Register for Updates
Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke
NCT06615973
Recruiting
Background: Stroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive strokes have mental impairment or dementia. Medical factors, such as the severity of the stroke, affect whether a person will have mental impairment afterward. But social factors, such as education and ethnicity, seem to play a role as well. Researchers want to learn more about how social and lifestyle factors affect a person s chances of mai... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Stroke, Brain Disease, Vascular Diseases, Cerebrovascular Disorder
Register for Updates
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
NCT06603818
Recruiting
Background: Metastatic colorectal cancer (mCRC) is cancer that has spread beyond the colon and rectum. Most people with mCRC die within 5 years. New immune-based treatments are making progress with some types of colon cancer. But these treatments do little for people with a type of cancer that is microsatellite stable (MSS). MSS is a specific cancer biomarker. Better treatments are needed. Objective: To test 2 drugs (tiragolumab and atezolizumab) combined with radiation therapy in people with... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
Register for Updates
Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
NCT06595953
Recruiting
Background: Anxiety disorders are becoming more common among children and teenagers. Anxiety can lead to long-term physical and mental problems, such as depression. Treatments for anxiety disorders include medications as well as cognitive behavioral therapy (CBT); CBT is a form of talking therapy. Both approaches work in only about 50 percent of cases. A new approach, called gaze-contingent music reward therapy (GCMRT), may help. Objective: To find out whether GCMRT combined with CBT is more... Read More
Gender:
ALL
Ages:
Between 8 years and 17 years
Trial Updated:
08/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Psychiatric Disorders, Anxiety Disorders
Register for Updates
Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making
NCT06561828
Recruiting
Background: People with substance use disorder (SUD) often have changes in brain function that can make it difficult to control drug-seeking behavior. These changes may heighten the urge to use drugs or lessen the desire to seek nondrug-related rewards. Researchers want to know how a technique called transcranial magnetic stimulation (TMS) may cause changes in brain activity that may help people with SUD. Objective: To test TMS in healthy volunteers. Eligibility: Healthy people aged 18 to 4... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/13/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Normal Physiology
Register for Updates